Tag: heart disease

May 13, 2020

Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) has entered into an agreement with Canaccord Genuity.
May 6, 2020

Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19

Cardiol Therapeutics is pleased to announce the filing of a new patent application covering the use of cannabidiol (CBD) to...
April 1, 2020
March 27, 2020

Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A

Cardiol Therapeutics Inc. filed its audited Year-end Financial Statements and Management's Discussion and Analysis for the year ended December 31,...
March 18, 2020

Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.

Cardiol Therapeutics Inc. has signed a supplier agreement to offer its pharmaceutically produced cannabidiol to Medical Cannabis by Shoppers.
March 5, 2020

Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation

Cardiol Therapeutics has received a No Objection Letter from Health Canada to conduct a Phase 1 study of its pharmaceutically...
January 15, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

Dalton Pharma Services, has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada.